14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PCVX vs MLTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Vaxcyte, Inc. (PCVX) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). PCVX carries a Unified Composite Score of 47.3/100 (HOLD) at $62.04 (N/M Forward P/E, 0.0% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: PCVX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PCVX vs MLTX. Trailing 12-month operating profitability (PCVX 0.0% vs MLTX 0.0%) and valuation multiples (PCVX N/M vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PCVX vs MLTX Key Questions & Quantitative Answers
As of Nov 16, 2026, Vaxcyte, Inc. (PCVX) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). PCVX carries a Unified Composite Score of 47.3/100 (HOLD) at $62.04 (N/M Forward P/E, 0.0% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PCVX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PCVX leads the Growth & Scale pillar: PCVX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MLTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PCVX generates N/A in USD-normalized revenue versus N/A for MLTX. In operating R&D and SG&A reinvestment, PCVX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MLTX.
PCVX and MLTX trade at balanced relative valuation multiples. PCVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PCVX (-42.7% ROE) versus MLTX (-81.5% ROE) capital efficiency.
In options market volatility and institutional positioning, PCVX carries 52.2% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 57% Vol realized risk). By comparison, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.